Patents by Inventor Chaofeng LONG

Chaofeng LONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLIDINE DERIVATIVES AS PPAR AGONISTS
    Publication number: 20190225597
    Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholgangitis, dyslipidenmia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 12, 2017
    Publication date: July 25, 2019
    Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
  • Hydroxyl purine compounds and use thereof
    Patent number: 10278973
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: May 7, 2019
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Xiaoxin Chen, Peng Zhang, Xing Liu, Li Zhang, Zhuowei Liu, Shuhui Chen, Chaofeng Long
  • TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20190119217
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Application
    Filed: April 7, 2016
    Publication date: April 25, 2019
    Inventors: Chaofeng LONG, Zhengxia CHEN, Xiaoxin CHEN, Yang ZHANG, Zhuowei LIU, Peng LI, Shuhui CHEN, Guibai LIANG, Cheng XIE, Zhengwei LI, Zhifei FU, Guoping HU, Jian LI
  • CRYSTAL FORM OF 4H-PYRAZOLO[1,5-alpha]BENZOIMIDAZOLE COMPOUND, PREPARATION METHOD THEREOF AND INTERMEDIATE THEREOF
    Publication number: 20180305361
    Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.
    Type: Application
    Filed: October 27, 2016
    Publication date: October 25, 2018
    Inventors: Lingyun WU, Chaofeng LONG, Peng ZHANG, Xiaoxin CHEN, Li ZHANG, Zhuowei LIU, Zheng WANG, Shuhui CHEN, Lijuan CHEN
  • Hydroxyl purine compounds and applications thereof
    Patent number: 10098885
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: October 16, 2018
    Assignee: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen
  • HYDROXYL PURINE COMPOUNDS AND USE THEREOF
    Publication number: 20180148451
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 31, 2018
    Inventors: Linyun WU, Xiaoxin CHEN, Peng ZHANG, Xing LIU, Li ZHANG, Zhuowei LIU, Shuhui CHEN, Chaofeng LONG
  • HYDROXYL PURINE COMPOUNDS AND USE THEREOF
    Publication number: 20180140607
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 5, 2016
    Publication date: May 24, 2018
    Inventors: Lingyun WU, Xiaoxin CHEN, Peng ZHANG, Xing LIU, Li ZHANG, Zhuowei LIU, Shuhui CHEN, Chaofeng LONG
  • HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20180098990
    Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells.
    Type: Application
    Filed: March 17, 2016
    Publication date: April 12, 2018
    Inventors: Lijuan CHEN, Chaofeng LONG, Xiaoxin CHEN, Zhuowei LIU, Haoyu YE, Chenshi XIE
  • Quinoline derivatives as SMO inhibitors
    Patent number: 9938292
    Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: April 10, 2018
    Assignee: Guangdong Zhongsheng Pharmaceutical Co., Ltd
    Inventors: Hao Wu, Chaofeng Long, Jun Lin, Xiaoxin Chen, Yunhui Li, Zhuowei Liu, Changqing Wei, Lijuan Chen, Shuhui Chen
  • HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF
    Publication number: 20170326149
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Application
    Filed: September 22, 2015
    Publication date: November 16, 2017
    Applicants: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD, MEDSHINE DISCOVERY INC.
    Inventors: Lingyun WU, Chaofeng LONG, Peng ZHANG, Xiaoxin CHEN, Li ZHANG, Zhuowei LIU, Jian LI, Shuhui CHEN
  • QUINOLINE DERIVATIVES AS SMO INHIBITORS
    Publication number: 20170174703
    Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.
    Type: Application
    Filed: March 16, 2015
    Publication date: June 22, 2017
    Inventors: Hao WU, Chaofeng LONG, Jun LIN, Xiaoxin CHEN, Yunhui LI, Zhuowei LIU, Changqing WEI, Lijuan CHEN, Shuhui CHEN